Приказ основних података о документу
Ruthenium(II) p-cymene complex bearing 2,2 `-dipyridylamine targets caspase 3 deficient MCF-7 breast cancer cells without disruption of antitumor immune response
dc.creator | Kaluđerović, Goran N. | |
dc.creator | Krajnović, Tamara | |
dc.creator | Momčilović, Miljana | |
dc.creator | Stošić-Grujičić, Stanislava | |
dc.creator | Mijatović, Sanja | |
dc.creator | Maksimović-Ivanić, Danijela | |
dc.creator | Hey-Hawkins, Evamarie | |
dc.date.accessioned | 2016-05-23T11:00:52Z | |
dc.date.issued | 2015 | |
dc.identifier.issn | 1873-3344 | |
dc.identifier.uri | https://radar.ibiss.bg.ac.rs/handle/123456789/2322 | |
dc.description.abstract | {[}Ru(eta(6)-p-cym)Cl\{dpa(CH2)(4)COOEt\}]{[}PF6] (cym = cymene; dpa = 2,2'-dipyridylamine; complex 2) was prepared and characterized by elemental analysis, IR and multinuclear NMR spectroscopy, as well as ESI-MS and X-ray structural analysis. The structural analog without a side chain {[}Ru(eta(6)-p-cym)Cl(dpa)]{[}PF6] (1) as well as 2 were investigated in vitro against 518A2, SW480, 8505C, A253 and MCF-7 cell lines. Complex 1 is active against all investigated tumor cell lines while the activity of compound 2 is limited only to caspase 3 deficient MCF-7 breast cancer cells, however, both are less active than cisplatin. As CD4(+)Th cells are necessary to trigger all the immune effector mechanisms required to eliminate tumor cells, besides testing the in vitro antitumor activity of 1 and 2, the effect of ruthenium(II) complexes on the cells of the adaptive immune system have also been evaluated. Importantly, complex 1 applied in concentrations which were effective against tumor cells did not affect immune cell viability, nor did exert a general immunosuppressive effect on cytokine production. Thus, beneficial characteristics of 1 might contribute to the overall therapeutic properties of the complex. (C) 2015 Elsevier Inc. All rights reserved. | en |
dc.description.sponsorship | European Union; Free State of Saxony {[}100099597]; Ministry of Education, Science and Technological Development of the Republic of Serbia {[}173013] | en |
dc.language | English | |
dc.rights | restrictedAccess | |
dc.source | Journal of Inorganic Biochemistry | |
dc.subject | Ruthenium(II) | |
dc.subject | Cisplatin | |
dc.subject | Anticancer drugs | |
dc.subject | Immune cells | |
dc.subject | Cytokines | |
dc.title | Ruthenium(II) p-cymene complex bearing 2,2 `-dipyridylamine targets caspase 3 deficient MCF-7 breast cancer cells without disruption of antitumor immune response | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Крајновић, Тамара; Стошић-Грујичић, Станислава Д.; Хеy-Хаwкинс, Евамарие; Максимовић, Данијела Д.; Калуђеровић, Горан Н.; Момчиловић, Миљана Б.; Мијатовић, Сања A.; | |
dc.citation.volume | 153 | |
dc.identifier.doi | 10.1016/j.jinorgbio.2015.09.006 | |
dc.identifier.scopus | 2-s2.0-84949784256 | |
dc.identifier.wos | 000367563200036 | |
dc.citation.spage | 315 | |
dc.citation.epage | 321 | |
dc.type.version | publishedVersion | en |
Документи
Датотеке | Величина | Формат | Преглед |
---|---|---|---|
Уз овај запис нема датотека. |